The four-year randomized Phase II clinical trial, named SOLACE2, brought together leading institutions including the University of Sydney NHMRC Clinical Trials Centre, RMIT University, and the Walter and Eliza Hall Institute of Medical Research (WEHI). Coordinated by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), this ambitious study set out to explore advanced strategies aimed at priming the immune system to bolster the efficacy of PARP inhibitor therapy in women with platinum-sensitive ovarian cancer. PARP inhibitors work by blocking the PARP enzyme, crucial for repairing DNA damage in cancer cells, thus rendering them unable to maintain their genomic integrity.

While PARP inhibitor therapy is currently prescribed primarily to patients with homologous recombination deficiency (HRD-positive tumors), marked by defective DNA repair mechanisms, clinical experience has shown contradictory outcomes. Some women with HRD-negative tumors still respond to PARP inhibitors, while others with HRD-positive ovarian cancer do not, highlighting the inadequacy of current biomarkers to fully predict therapeutic responsiveness. This discrepancy has driven researchers to seek more nuanced, dynamic predictive tools beyond genomic tests.

In this context, RMIT’s Distinguished Professor Magdalena Plebanski, co-senior author and lead researcher, emphasizes the novelty of a new immune-based blood test developed and evaluated during the SOLACE2 trial. Unlike traditional HRD testing that relies on static genetic information from tumor biopsies, this test offers real-time insight into the patient’s immune system response. It measures a composite “biomarker signature” that combines levels of immune activation markers indicating the mobilization of cytotoxic immune cells toward tumor sites, alongside indicators of inflammatory pathways that may hinder treatment success and fuel cancer progression.

Published in Nature Communications, the research unveils how these RMIT-patented immune biomarkers outperform the current HRD test’s predictive capacity. This advancement has far-reaching implications because the standard HRD assay depends on viable tumor tissue samples and involves complex DNA repair analyses, which are not always feasible or representative of the cancer’s evolving biology. Tumor DNA repair proficiency can fluctuate over time, especially under treatment pressure, potentially misleading clinicians relying solely on static tests.

Professor Plebanski elucidates that their immune-focused approach better captures the dynamic interplay between immune surveillance and tumor biology. By tracking effector T cell activation and migration in the bloodstream, the test offers a directly relevant indication of how the patient’s body is naturally combating the cancer at any given moment. This real-time biomarker assessment can thus refine patient selection for PARP inhibitor therapy, ensuring more women who stand to benefit receive this potent therapeutic modality, while sparing others from ineffective treatments and associated toxicities.

A critical dimension of the SOLACE2 findings came from the expertise of WEHI’s Professor Clare Scott AM, joint-senior author, and an oncologist deeply versed in ovarian cancers. Scott highlights the integral role played by immune cell trafficking into the tumor microenvironment. Their capacity to infiltrate tumors and mediate cytolytic activity against cancer cells emerges as a decisive factor in response to PARP inhibitors, especially when combined with immunotherapy agents. Understanding and eventually manipulating this immune migration holds promise not just for prognosis but also for developing adjunct treatments that potentiate immune-mediated tumor control.

Despite these promising results, the novel blood test is not yet available in routine clinical practice. It requires further validation through larger, multi-center studies and regulatory approval before becoming an accessible tool for oncologists worldwide. Nonetheless, the SOLACE2 trial’s results underscore a paradigm shift towards integrating immune function assays into personalized cancer treatment algorithms, which could herald a new era in ovarian cancer care.

The SOLACE2 clinical trial also assessed the therapeutic benefit of immune priming with a combination of olaparib, durvalumab, and low-dose cyclophosphamide. Clinical lead Professor Chee Khoon Lee from the University of Sydney’s NHMRC Clinical Trials Centre notes that although the trial exhibited encouraging signs of delaying cancer recurrence with this three-month immune priming approach followed by PARP inhibitor and immunotherapy, the sample size precluded definitive conclusions. More extensive research will be essential to confirm these clinical benefits.

Nonetheless, the study achieved a crucial breakthrough by simultaneously unveiling a prognostic blood signature predictive of therapy response. This signature has the transformative potential to guide clinicians in tailoring treatments with unprecedented precision, transcending the limitations imposed by genomic biomarkers alone. Effectively, patients could be stratified based on dynamic immune responsiveness, enabling more accurate and personalized ovarian cancer management.

The trial’s findings emphasize the complex and evolving nature of ovarian cancer biology, underscoring the inadequacy of relying solely on DNA repair status as a predictive marker. By shifting the focus to immunological indicators detectable through a simple blood test, the research team envisions a future where treatment decisions incorporate real-time biological data from the host immune environment, leading to more nuanced and effective therapeutic regimens.

This study marks a watershed moment in ovarian cancer research, unveiling a robust path forward for integrating immunological insights into clinical oncology practice. The researchers’ multidisciplinary approach—uniting clinical trials, immunology, molecular biology, and patient-centered methodology—sets a new standard for precision oncology aimed at improving survival and quality of life for women facing this formidable disease.

The SOLACE2 results, detailed in the publication titled “Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial,” represent a beacon of hope for ovarian cancer patients and clinicians alike. Continued research and validation will be critical to translate these scientific advances into routine clinical use, ultimately transforming ovarian cancer treatment paradigms and patient outcomes globally.

Subject of Research: People

Article Title: Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial

News Publication Date: 5-Nov-2025

Web References:
https://www.nature.com/articles/s41467-025-64130-6
http://dx.doi.org/10.1038/s41467-025-64130-6

References:
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial, Nature Communications, DOI: 10.1038/s41467-025-64130-6

Image Credits: WEHI

Keywords: Cancer, Ovarian cancer, Clinical medicine, Biomarkers, Medical diagnosis

ZNFX1’s role as a master regulator is multi-faceted, having been identified through an extensive study that involved scrutinizing patient databases across multiple institutions, namely UMSOM, Indiana University School of Medicine-Bloomington, and Johns Hopkins University School of Medicine. Researchers found that elevated levels of ZNFX1 correlate strongly with responses to therapies in patients suffering from advanced-stage ovarian cancer. As a result, ZNFX1 holds potential as a predictive biomarker for determining therapy outcomes in these patients.

The studied data revealed that high ZNFX1 expression levels not only correspond to effective therapeutic responses but also correlate with increased overall survival rates, particularly noted in a phase three clinical trial where patients were treated with the anti-cancer drug bevacizumab, combined with chemotherapy. This correlation suggests that ZNFX1 could be integral in developing more individualized therapy regimens tailored to enhance patient outcomes.

Additionally, the research illuminated the interaction between ZNFX1 and specific cancer treatments, demonstrating that DNA methyltransferase inhibitors and PARP inhibitors can elevate ZNFX1 expression. This increase facilitates tumor suppressive inflammatory responses within cancer cells, indicating that these existing treatments may have enhanced efficacy when ZNFX1 is taken into account. Such insights underscore the intricate relationships between genetic regulators and therapeutic agents in devising a more effective approach to cancer treatment.

Senior author, Dr. Feyruz V. Rassool, who serves as a professor of radiation oncology at UMSOM and co-director of the experimental therapeutics program at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, remarked that this discovery of ZNFX1 as a potential biomarker can significantly bolster personalized treatment strategies for ovarian cancer patients. The anticipation is that refining treatment options based on ZNFX1 levels will facilitate more directed and successful therapy experiences for those facing ovarian cancer.

Dr. Taofeek K. Owonikoko, the Executive Director of the Greenebaum Comprehensive Cancer Center and a distinguished oncology professor at UMSOM, emphasized the potential clinical implications of identifying ZNFX1. The move towards more personalized therapies in ovarian cancer is poised to open new avenues for research, shifting the paradigm from traditional one-size-fits-all treatment approaches to more individualized strategies that take genetic markers into consideration.

The research was financially supported through grants from various prominent organizations, including the Adelson Medical Research Foundation and the Van Andel Institute Stand Up to Cancer Epigenetics Dream Team, alongside a Specialized Program of Research Excellence grant from the National Cancer Institute awarded to The Coriell Institute for Medical Research and the Van Andel Institute in 2021. This financial backing is indicative of the high-stakes significance attributed to the ongoing endeavors in cancer research, which aim to transform the therapeutic landscape.

Dr. Rassool, alongside a robust team comprising Ken Nephew from the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and Stephen B. Baylin from The Sidney Kimmel Comprehensive Care Center at Johns Hopkins, leads a collaborative effort involving nearly 20 scientists from six institutions. Their joint effort not only aims to validate ZNFX1’s role in ovarian cancer but also seeks innovative therapies based on the understanding of epigenetic mechanisms in cancer biology.

As the University of Maryland School of Medicine celebrates its long-standing tradition of excellence in research, it consistently ranks as a premier institution within the realm of biomedical research, fostering collaborations that span various specialties and institutions. The findings concerning ZNFX1 epitomize the university’s commitment to pioneering meaningful advancements in medical science and cancer treatments.

The implications of this research extend beyond ovarian cancer, as learning about ZNFX1’s functionality could influence therapeutic strategies in other cancers as well. The comprehensive nature of the study provides a framework that could be applicable to a wide array of malignancies where personalized medicine is gaining traction through genetic understanding.

This groundbreaking research reflects the dynamic synergy of collaboration among world-class institutions dedicated to unraveling the complexities of cancer. The potential of ZNFX1 as a biomarker represents a beacon of hope not only for patients but also for the scientific community in its ongoing battle against cancer.

As this research gains recognition, the anticipated clinical trials based on these findings may soon set new benchmarks for ovarian cancer treatment protocols, echoing the importance of rigorous scientific inquiry. The expectation is that as ZNFX1’s role is further elucidated, it will serve as a cornerstone in redefining treatment regimens and improving survival rates for patients facing one of the most challenging cancer diagnoses.

Innovations such as these are critical in clinical oncology’s trajectory, influencing both current practices and future research directions designed to combat cancer and its resistance mechanisms. The drive towards understanding genetic profiles like that of ZNFX1 is paramount, heralding an era where tailored therapies could significantly augment patient well-being and clinical success rates.

Ultimately, the research surrounding ZNFX1 embodies a holistic approach to cancer treatment, bridging laboratory discoveries with clinical applications that could reshape the future of oncology. As the field of cancer research continuously evolves, this discovery reinforces the significance of personalized medicine and the enduring efforts to uncover genetic underpinnings that could lead to more effective therapeutic regimes.

Subject of Research: Master Regulator Gene ZNFX1 in Ovarian Cancer Treatment
Article Title: ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer
News Publication Date: 3-Apr-2025
Web References: Cancer Research Article
References: 10.1158/0008-5472.CAN-24-1286
Image Credits: University of Maryland School of Medicine
Keywords: Ovarian Cancer, Cancer Research, ZNFX1, Biomarkers, Personalized Medicine